Paolo Paoletti has been appointed as executive chairman of multiple myeloma specialist Kesios Therapeutics.
He joins the company from UK pharma major GlaxoSmithKline where he was the first appointed president of GSK Oncology. During his time at GSK, seven new medicines to treat different cancers were approved globally.
Kesios is based at the Imperial incubator in South Kensington, London, and was created to develop and commercialize research from the Department of Medicine at Imperial College London. In October 2014, the holding company Imperial Innovations completed a seed investment of $2.8 million in Kesios.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze